<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02148913</url>
  </required_header>
  <id_info>
    <org_study_id>2014-067</org_study_id>
    <nct_id>NCT02148913</nct_id>
  </id_info>
  <brief_title>Phase I: Melphalan, Bendamustine and Carfilzomib for Autologous Transplant in Multiple Myeloma</brief_title>
  <official_title>A Phase I Study of Melphalan, Bendamustine, and Carfilzomib for Autologous Hematopoietic Stem Cell Transplantation in Patients With Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spectrum Health Hospitals</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Spectrum Health Hospitals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase I clinical trial. Patients with a diagnosis of multiple myeloma undergoing
      autologous transplantation will receive a preparative regimen of melphalan, bendamustine, and
      carfilzomib. We hypothesize that the addition of carfilzomib to a conditioning regimen of
      melphalan and bendamustine in the setting of autologous transplantation for multiple myeloma
      is feasible and safe.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 2014</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose Limiting Toxicity</measure>
    <time_frame>Assessed daily (while inpatient) through clinical and laboratory examinations up to 90 days.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Engraftment</measure>
    <time_frame>Assessed daily (while inpatient) through clinical and laboratory examinations up to 90 days.</time_frame>
    <description>Engraftment of Neutrophils: ANC recovery is defined as an absolute neutrophil count (ANC) of ≥ 0.5 x 109/L for three consecutive laboratory values obtained on different days. The day used as neutrophil engraftment is the date of the first of three laboratory values.
Engraftment of Platelets: Platelet engraftment is defined as a platelet count ≥ 20 x 109/L for 3 consecutive measurements obtained on different days. The patient must not have received a platelet infusion for seven consecutive days prior to the first day being considered. The day used as platelet engraftment is the date of the first of three laboratory values.
Graft Failure: Graft failure includes failure to achieve neutrophil engraftment by day 22.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Response Rate</measure>
    <time_frame>Disease assessment at day +100, +180, and +365 (+/- 7 days).</time_frame>
    <description>Find the response rate of the combination of melphalan, bendamustine, and carfilzomib as a conditioning regimen in patients with multiple myeloma undergoing autologous transplantation.</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">26</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Cohort 1: Carfilzomib 15 mg/m2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Carfilzomib 15 mg/m2 on days -2, -1, +5, and +6 IV over 10 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: Carfilzomib 20 mg/m2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Carfilzomib 20 mg/m2 on days -2, -1, +5, and +6 IV over 10 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2b: Carfilzomib 20 mg/m2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Carfilzomib 20 mg/m2 on days -2, -1 and +5 IV over 10 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: Carfilzomib 27mgm2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Carfilzomib 27 mg/m2 on days -2, -1 and +5 IV over 10 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cohort 1: Carfilzomib 15 mg/m2</intervention_name>
    <description>Carfilzomib 20 mg/m2 on days -29, -28, -22, -21, -15, and -14 Bendamustine 120 mg/m2 on day -2 and 100 mg/m2 day -1 Melphalan 100 mg/m2 on day -2 and day -1 Carfilzomib 15 mg/m2 on day -2, -1, + 5 and +6</description>
    <arm_group_label>Cohort 1: Carfilzomib 15 mg/m2</arm_group_label>
    <other_name>Carfilzomib - Kyprolis</other_name>
    <other_name>Bendamustine - Treanda</other_name>
    <other_name>Melphalan - Alkeran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cohort 2: Carfilzomib 20 mg/m2</intervention_name>
    <description>Carfilzomib 20 mg/m2 on days -29, -28, -22, -21, -15, and -14 Bendamustine 120 mg/m2 on day -2 and 100 mg/m2 day -1 Melphalan 100 mg/m2 on day -2 and day -1 Carfilzomib 20 mg/m2 on day -2, -1, + 5 and +6</description>
    <arm_group_label>Cohort 2: Carfilzomib 20 mg/m2</arm_group_label>
    <other_name>Carfilzomib - Kyprolis</other_name>
    <other_name>Bendamustine - Treanda</other_name>
    <other_name>Melphalan - Alkeran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cohort 2b: Carfilzomib 20 mg/m2</intervention_name>
    <description>Carfilzomib 20 mg/m2 on days -29, -28, -22, -21, -15, and -14 Bendamustine 120 mg/m2 on day -2 and 100 mg/m2 day -1 Melphalan 140 mg/m2 on day -1 Carfilzomib 20 mg/m2 on day -2, -1 and + 5</description>
    <arm_group_label>Cohort 2b: Carfilzomib 20 mg/m2</arm_group_label>
    <other_name>Carfilzomib - Kyprolis</other_name>
    <other_name>Bendamustine - Treanda</other_name>
    <other_name>Melphalan - Alkeran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cohort 3b: Carfilzomib 27 mg/m2</intervention_name>
    <description>Carfilzomib 20 mg/m2 on days -29, -28, -22, -21, -15, and -14 Bendamustine 120 mg/m2 on day -2 and 100 mg/m2 day -1 Melphalan 140 mg/m2 on day -1 Carfilzomib 27 mg/m2 on day -2, -1 and + 5</description>
    <arm_group_label>Cohort 3: Carfilzomib 27mgm2</arm_group_label>
    <other_name>Carfilzomib - Kyprolis</other_name>
    <other_name>Bendamustine - Treanda</other_name>
    <other_name>Melphalan - Alkeran</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of multiple myeloma

          -  At least 2 x 106 CD34+ cells/kg have been collected from the patient and cryopreserved
             for ASCT

          -  Greater than 18 years

          -  Karnofsky score greater than 70%

          -  No evidence of progressive bacterial, viral, or fungal infection

          -  Absolute neutrophil count above 1000

          -  Platelet count above 50,000

          -  Hemoglobin above 8 g/dL

          -  Creatinine clearance greater than 50 mL/min

          -  Total bilirubin, ALT, and AST less than 2 x the upper limit of normal

          -  Alkaline phosphatase less than or equal to 250 IU/L

          -  Left Ventricular Ejection Fraction (LVEF) greater than or equal to 45%

          -  Adjusted Carbon Monoxide Diffusing Capacity (DLCO) greater than or equal to 60%

          -  Negative HIV serology

          -  Recovered from toxicity of previous chemotherapy (excludes grade 1 neurotoxicity and
             hematological toxicity)

          -  Patients with a pre-transplant disease status consistent with a very good partial
             response (VGPR), partial response (PR), stable disease (SD), progressive disease (PD),
             or relapse from complete remission (CR).

        Exclusion Criteria:

          -  Patients who are refractory to carfilzomib. Refractory is defined as disease
             progression while on carfilzomib therapy after receiving at least two cycles of
             treatment.

          -  Patients with a complete response (CR) (including near CR and stringent CR) to
             conventional induction therapy and proceeding to transplantation.

          -  Pregnant or nursing females or women of reproductive capability who are unwilling to
             use effective contraception. A woman of reproductive capability is one who has not
             undergone a hysterectomy (removal of the womb), has not had both ovaries removed, or
             has not been post-menopausal (stopped menstrual periods) for more than 24 months in a
             row.

          -  Male subjects who refuse to practice effective barrier contraception during the entire
             study treatment period and through a minimum of 30 days after the last dose of study
             drug, or completely abstain from heterosexual intercourse. This must be done even if
             they are surgically sterilized (ie, post-vasectomy).

          -  Patient with Grade 2 peripheral neuropathy

          -  Inability to provide informed consent

          -  Patient had myocardial infarction within 6 months prior to enrollment or has New York
             Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe
             uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute
             ischemia or active conduction system abnormalities.

          -  Prior to study entry, any ECG abnormality at screening must be documented by the
             investigator as not medically relevant.

          -  Known allergies to any of the components of the investigational treatment regimen or
             required ancillary treatments.

          -  Serious medical or psychiatric illness likely to interfere with participation in this
             clinical study.

          -  Diagnosed or treated for another malignancy within 3 years of enrollment (with the
             exception of non-melanoma skin cancer).

          -  Participation in clinical trials with other investigational agents not included in
             this trial, within 14 days of the start of this trial and throughout the duration of
             this trial.

          -  Prisoner
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Muneer H Abidi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Spectrum Health Hospitals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Spectrum Health</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 23, 2014</study_first_submitted>
  <study_first_submitted_qc>May 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2014</study_first_posted>
  <last_update_submitted>April 16, 2018</last_update_submitted>
  <last_update_submitted_qc>April 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Spectrum Health Hospitals</investigator_affiliation>
    <investigator_full_name>Muneer H. Abidi</investigator_full_name>
    <investigator_title>Adult Blood and Marrow Transplant Physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Bendamustine Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

